ALTRAVAX, INC.

Basic Information

3233 15TH ST S
FARGO, ND, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 832765932
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of a Universal Influenza B Vaccine

    Amount: $300,000.00

    DESCRIPTION provided by applicant Influenza is associated with deaths in the US each year and vaccination is the best strategy for the prevention of influenza A major obstacle to the ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    Amount: $532,838.00

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of d ...

    STTR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Novel Subunit Vaccines against Varicella Zoster Virus

    Amount: $597,176.00

    DESCRIPTION provided by applicant Varicella zoster virus VZV is a neurotropic alpha herpesvirus that causes varicella chickenpox and establishes latency in the sensory ganglia Reactivation of ...

    SBIR Phase I 2014 Department of Health and Human Services National Institutes of Health
  4. Novel Tetravalent Vaccines for Dengue Virus

    Amount: $598,472.00

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmissio ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccin ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Novel Therapeutic Vaccines for Chronic HBV

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals bu ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. VLP-Based Antibody-Inducing Vaccines for HIV-1

    Amount: $599,688.00

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV- ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. Improved Vaccines for Influenza B Virus

    Amount: $598,391.00

    DESCRIPTION (provided by applicant): Influenza is a major cause of morbidity and mortality around the world. In the United States, seasonal epidemics of flu occur from late fall to early spring affec ...

    SBIR Phase I 2010 Department of Health and Human Services
  9. Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates

    Amount: $599,074.00

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV- ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government